Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9NPG8

UPID:
ZDHC4_HUMAN

ALTERNATIVE NAMES:
Zinc finger DHHC domain-containing protein 4; Zinc finger protein 374

ALTERNATIVE UPACC:
Q9NPG8; A4D2N9; Q53EV7; Q6FIB5; Q9H0R9

BACKGROUND:
The enzyme Palmitoyltransferase ZDHHC4, with alternative names Zinc finger DHHC domain-containing protein 4 and Zinc finger protein 374, is essential for the palmitoylation of protein substrates such as the D(2) dopamine receptor DRD2. This post-translational modification process is critical for the regulation of protein localization, stability, and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Palmitoyltransferase ZDHHC4 holds significant promise for the development of new therapeutic approaches. Given its role in the critical process of protein palmitoylation, targeting ZDHHC4 could lead to breakthroughs in treating diseases where protein function regulation is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.